{
    "nct_id": "NCT04402060",
    "official_title": "A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19",
    "inclusion_criteria": "* Be at least 18 years of age at time of informed consent\n* Diagnosis of active SARS CoV 2 infection using viral RNA or viral antigen within 7 days of screening\n* Respiratory failure requiring oxygen supplementation or either invasive or noninvasive mechanical ventilation with PaO2/FiO2 ratio >100 mm Hg. Respiratory failure cannot be fully explained by cardiac failure or fluid overload.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Treatment with immune checkpoint inhibitors, or other immunomodulators within 3 months prior to study enrollment (however, treatment with convalescent plasma, steroids, IL-6 inhibitors, and antiviral agents is NOT excluded)\n* Active bacterial, fungal, or parasitic infection\n* History of neuromuscular degenerative disease (eg, amyotrophic lateral sclerosis, Duchenne muscular dystrophy, or multiple sclerosis)\n* Current participation in an interventional clincial trial\n* Subjects who have, at screening, been on mechanical ventilation for >7 days Have evidence of kidney and liver failure at screening\n* Have a hereditary complement deficiency\n* Pregnancy or breastfeeding",
    "miscellaneous_criteria": ""
}